-- Announced new clinical trial agreement with Pfizer to evaluate 
      palazestrant in combination with atirmociclib in ER+/HER2- metastatic 
      breast cancer 
 
   -- Initiated OPERA-02 Phase 3 trial of palazestrant in combination with 
      ribociclib in frontline ER+/HER2- metastatic breast cancer 
 
   -- Presented compelling new data from Phase 1b/2 study of palazestrant plus 
      ribociclib at ESMO 2025 
 
   -- Ended the quarter with $329.0 million in cash, cash equivalents, and 
      marketable securities 

SAN FRANCISCO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today reported financial and operating results for the third quarter ended September 30, 2025.

"We have made significant progress advancing our programs this quarter, highlighted by the initiation of the Phase 3 OPERA-02 trial evaluating palazestrant in combination with ribociclib in the frontline setting and the presentation of compelling data at ESMO that further positions palazestrant to become a potential best-in-class backbone endocrine therapy for ER+/HER2- metastatic breast cancer," said Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer of Olema Oncology. "Our clinical trial agreement with Pfizer to combine palazestrant with atirmociclib further underscores our confidence in palazestrant's activity in combination with other agents in the metastatic setting."

Bohen continued, "Enrollment in the OPERA-01 trial evaluating palazestrant as a monotherapy in second- and third-line ER+/HER2- metastatic breast cancer continues to progress well and we remain on track for top-line data in the second half of next year. The Phase 1/2 study of our KAT6 inhibitor, OP-3136, recently expanded into combinations with fulvestrant and palazestrant and continues to benefit from strong investigator interest. As we look ahead to 2026, we remain focused on sustaining positive momentum across the business, transforming the breast cancer treatment paradigm, and bringing palazestrant to market."

Recent Progress

   -- Announced a clinical trial collaboration and supply agreement with Pfizer 
      to evaluate the safety and combinability of palazestrant plus 
      atirmociclib, Pfizer's investigational, highly selective-CDK4 inhibitor, 
      in a Phase 1b/2 study in patients with estrogen receptor-positive, human 
      epidermal growth factor receptor 2-negative (ER+/HER2-) metastatic breast 
      cancer. 
 
   -- Initiated the OPERA-02 Phase 3 trial of palazestrant in combination with 
      ribociclib in frontline ER+/HER2- metastatic breast cancer. 
 
   -- Presented updated data from the Phase 1b/2 study of palazestrant plus 
      ribociclib at the European Society for Medical Oncology (ESMO) Congress 
      2025, demonstrating encouraging activity in both ESR1 mutant and 
      wild-type patients. 
 
   -- Continued enrollment in the OPERA-01 Phase 3 trial of palazestrant as a 
      monotherapy in second- and third-line ER+/HER2- metastatic breast cancer. 
 
   -- Advanced the Phase 1 study evaluating the safety, tolerability, 
      pharmacokinetics, pharmacodynamics, and preliminary efficacy of OP-3136, 
      as a monotherapy and in combination with fulvestrant and palazestrant, in 
      participants with advanced solid tumors. 

Anticipated Upcoming Events

   -- Initiate the Phase 1b/2 study evaluating palazestrant with atirmociclib 
      in ER+/HER2- metastatic breast cancer in Q4 2025. 
 
   -- Present trial-in-progress poster entitled "OPERA-02: a phase 3 randomized, 
      double-blind, active-controlled study of palazestrant with ribociclib 
      versus letrozole with ribociclib for the first-line treatment of ER+, 
      HER2- advanced breast cancer" at the San Antonio Breast Cancer Symposium 
      (SABCS) in December 2025. 
 
   -- Report initial clinical results for OP-3136 in mid-2026. 
 
   -- Report top-line data from OPERA-01 in the second half of 2026. 

Third Quarter 2025 Financial Results

Cash, cash equivalents, and marketable securities of $329.0 million as of September 30, 2025.

Net loss for the quarter ended September 30, 2025 was $42.2 million, as compared to $34.6 million for the quarter ended September 30, 2024. The increase in net loss for the third quarter was primarily related to increased spending on research and development activities as a result of the ongoing late-stage clinical trials for palazestrant and the advancement of OP-3136, partially offset by higher interest income earned from marketable securities.

GAAP research and development (R&D) expenses were $40.0 million for the quarter ended September 30, 2025, as compared to $33.2 million for the quarter ended September 30, 2024. The increase in R&D expenses was primarily related to increased spending on clinical development-related activities as Olema continues to advance palazestrant through late-stage clinical trials, and the advancement of OP-3136, partially offset by decreases in stock-based compensation expense of $1.7 million.

Non-GAAP R&D expenses were $37.4 million for the quarter ended September 30, 2025, excluding $2.6 million non-cash stock-based compensation expense. Non-GAAP R&D expenses were $28.9 million for the quarter ended September 30, 2024, which excluded $4.3 million non-cash stock-based compensation expense. A reconciliation of GAAP to non-GAAP financial measures used in this press release can be found at the end of this press release.

GAAP general and administrative (G&A) expenses were $5.9 million for the quarter ended September 30, 2025, as compared to $4.4 million for the quarter ended September 30, 2024. The increase in G&A expenses was primarily due to corporate-related costs, including increases in stock-based compensation expense of $0.3 million.

Non-GAAP G&A expenses were $4.3 million for the quarter ended September 30, 2025, excluding $1.7 million non-cash stock-based compensation expense. Non-GAAP G&A expenses were $3.0 million for the quarter ended September 30, 2024, excluding $1.3 million non-cash stock-based compensation expense. A reconciliation of GAAP to non-GAAP financial measures used in this press release can be found at the end of this press release.

About Olema Oncology

Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD), currently in two Phase 3 clinical trials. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical study. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit www.olema.com.

About Palazestrant (OP-1250)

Palazestrant (OP-1250) is a novel, orally available small molecule with dual activity as both a complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD). It is currently being investigated in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. In clinical studies, palazestrant completely blocks ER-driven transcriptional activity in both wild-type and mutant forms of metastatic ER+ breast cancer and has demonstrated anti-tumor efficacy along with attractive pharmacokinetics and exposure, favorable tolerability, central nervous system penetration, and combinability with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. Palazestrant has been granted U.S. Food and Drug Administration (FDA) Fast Track designation for the treatment of ER+/HER2- metastatic breast cancer that has progressed following one or more lines of endocrine therapy with at least one line given in combination with a CDK4/6 inhibitor. It is being evaluated as a single agent in the ongoing pivotal Phase 3 clinical trial, OPERA-01, and in combination with ribociclib in the ongoing pivotal Phase 3 clinical trial, OPERA-02. Palazestrant is also being evaluated in multiple Phase 1/2 studies in combination with ribociclib, palbociclib, alpelisib, everolimus, and atirmociclib.

About OP-3136

OP-3136 is a novel, orally available small molecule that potently and selectively inhibits lysine acetyltransferase 6 (KAT6), an epigenetic target that is dysregulated in breast and other cancers. In preclinical studies, OP-3136 has demonstrated significant anti-proliferative activity in ER+ breast cancer models and is combinable and synergistic with endocrine therapies including palazestrant and cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. The Investigational New Drug (IND) application for OP-3136 was cleared by the U.S. Food and Drug Administration (FDA) in December 2024 and patients are currently enrolling in the Phase 1 clinical study.

Non-GAAP Financial Information

(MORE TO FOLLOW) Dow Jones Newswires

November 10, 2025 07:00 ET (12:00 GMT)